Post-earnings recap
Reported
Thu, Aug 7, 2025
EPS actual
$-1.23
EPS est.
$-1.13
EPS surprise
-8.56%
1-day move
-2.28%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Crinetics Pharmaceuticals reported a wider-than-expected loss per share, which contributed to a 2.28% decline in stock price. The lack of revenue information and guidance may raise concerns among investors about the company's future performance. Management's defensive tone suggests they are navigating challenges that could impact growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.23 | N/A | -8.56% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautious outlook, highlighting the need for operational improvements. They acknowledged current market pressures affecting performance.
Management expressed concerns about ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.